PFA
NBIX icon

Pure Financial Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Pure Financial Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$280K Sell
1,662
-873
-34% -$130K ﹤0.01% 522
2026
Q1 		$334K Buy
2,535
+4
+0.2% +$531 ﹤0.01% 431
2025
Q4 		$359K Buy
2,531
+13
+0.5% +$1.88K 0.01% 382
2025
Q3 		$353K Sell
2,518
-178
-7% -$24.1K 0.01% 365
2025
Q2 		$339K Buy
+2,696
New +$309K 0.01% 364

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Pure Financial Advisors's NBIX Position: Q2 2026 in Review

Pure Financial Advisors reduced its Neurocrine Biosciences (NBIX) stake by 34% in Q2 2026, selling an estimated $130K and leaving 1,662 shares worth $280K. The position accounts for ﹤0.01% of the portfolio, ranked #522.

Pure Financial Advisors first reported a position in NBIX in Q2 2025 and has held it in 5 quarters since. The position peaked at $359K in Q4 2025. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Pure Financial Advisors held 1,662 shares of Neurocrine Biosciences worth $280K as of Q2 2026.
  • Pure Financial Advisors sold 873 Neurocrine Biosciences shares in Q2 2026, an estimated $130K.
  • Neurocrine Biosciences made up ﹤0.01% of Pure Financial Advisors's portfolio in Q2 2026, its #522 holding.
  • Pure Financial Advisors first reported a position in Neurocrine Biosciences in Q2 2025 and has held it in 5 quarters since.
  • Pure Financial Advisors's Neurocrine Biosciences position peaked at $359K in Q4 2025.
  • 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Pure Financial Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.